Skip to Main Content

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)


Diseases of the Musculoskeletal System

Phase III

What is the purpose of this trial?

Brief Summary:

To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.

  • Trial with
    Ra Pharmaceuticals, Inc.
  • Start Date
  • End Date

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 877.978.8343

  • Last Updated
  • Study HIC